INEGY 10 MG20 MG TABLETS

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

EZETIMIBE; SIMVASTATIN

Disponibbli minn:

MERCK SHARP & DOHME ISRAEL LTD

Kodiċi ATC:

C10AA01

Għamla farmaċewtika:

TABLETS

Kompożizzjoni:

SIMVASTATIN 20 MG; EZETIMIBE 10 MG

Rotta amministrattiva:

PER OS

Tip ta 'preskrizzjoni:

Required

Manifatturat minn:

MERCK SHARP & DOHME B.V., THE NETHERLANDS

Grupp terapewtiku:

SIMVASTATIN

Żona terapewtika:

SIMVASTATIN

Indikazzjonijiet terapewtiċi:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH.Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Data ta 'l-awtorizzazzjoni:

2012-04-30